ERBB2 and neoplasm: Previously, we found that 99mTc-HYNIC-H10F, a peptide-based radiotracer against subdomain II of HER2, was useful to predict the therapeutic response by noninvasively monitoring the decline in tumor HER2 expression after Traz therapy 44.